Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2012.560 | Asian Metastatic Colorectal Cancer Registry | Prof. MA Brigette |
| 2009.230 | Identifying an early indicator of drug efficacy in patients with advanced colorectal cancer - a prospective evaluation of circulating tumor cells, positron-emission tomography scan and RECIST criteria | Prof. MA Brigette |
| 2009.402 | Elucidating predictive biomarkers of response to cetuximab in local populations with advanced colorectal cancer | Prof. MA Brigette |
| 2010.202 | Prospective evaluation of plasma EBV DNA half-life and PET-CT scanning as a new tool in assessing early response to chemotherapy in patients with advanced nasopharyngeal carcinoma | Prof. MA Brigette |
| 2017.470 | Attitudes to supersized seamless trials in oncology (SUMO) - an international survey |
Prof. MA Brigette 馬碧如教授 |
| 2014.440 | A double-blind, randomised, placebo controlled Phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer refractory to standard therapies. | Prof. MA Brigette |
| 2017.110 | Developing patient derived xenograft and cell line models of cancer | Prof. MA Brigette |
| 2016.001 | Treatment of Recurrent and Advanced Metastatic Colorectal Cancer (TRACC) | Prof. MA Brigette |
| 2015.386 | Multicenter Phase II Study of Nivolumab in Previously Treated Patients with Recurrent and Metastatic Nasopharyngeal Carcinoma | Prof. MA Brigette |
| 2015.152 | Phase I/II study of aflibercept and the modified XELIRI regimen in the second-line treatment of metastatic colorectal cancer | Prof. MA Brigette |
| 2016.439 | The immunological mechanism of plasma EBV DNA clearance during radiotherapy in patients with nasopharyngeal carcinoma – a pilot study |
Prof. MA Brigette 馬碧如 |
| 2019.390 | Comprehensive Precision Oncology Program at The Chinese University of Hong Kong | Prof. MA Brigette |
| 2018.270 | A randomized study of neoadjuvant chemoradiotherapy with or without intensification with the FOLFOXIRI chemo-regimen for high-risk locally advanced rectal cancer |
Prof. MA Brigette 馬碧如 |
| 2012.191 | A randomized, double-blind, placebo-controlled phase III study of regorafenib plus best supportive care (BSC) versus placebo plus BSC in Asian subjects with metastatic colorectal cancer (CRC) who have progressed after standard therapy (CONCUR) | Prof. Ma Brigette Buig - Yue |
| 2012.044 | A Phase 1 Dose Escalation and Pharmacokinetic Study of Alisertib (MLN8237), an Aurora A Kinase Inhibitor, in Adult East Asian Patients With Advanced Solid Tumors or Lymphomas | Dr. Ma Brigette Buig Yue |
| 2012.129 | A phase I open-label dose escalation study with expansion to assess the safety and tolerability of INC280 in patients with c-MET dependent advanced solid tumors | Prof. MA Brigette Buig Yue |
| 2012.315 | A phase Ib dose escalation/randomized phase II, multicenter, open-label study of BYL719 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma | Prof. MA Brigette Buig Yue |
| 2012.232 | A Multinational, Randomized, Double-Blind Study of Aflibercept Versus Placebo with Irinotecan/5-FU Combination (FOLFIRI) in Patients with Metastatic Colorectal Cancer (MCRC) after failure of an Oxaliplatinb Based Regimen | Dr MA Brigette Buig Yue |
| 2013.294 | A phase Ib/II, open-label study of LJM716 in combination with BYL719 compared to taxane or irinotecan in patients with previously treated esophageal squamous cell carcinoma | Prof. MA Brigette Buig Yue |
| 2013.392 | A phase Ib trial of LEE011 in combination with everolimus (RAD001) and exemestane in the treatment of postmenopausal women with hormone receptor positive HER2 negative locally advanced or metastatic breast cancer | Prof. MA Brigette Buig Yue |
| 2018.436 | A Phase Ib, multicenter, open-label dose escalation and expansion platform study of select immunotherapy combinations in adult patients with triple negative breast cancer |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2020.457 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB PLUS TIRAGOLUMAB IN COMBINATION WITH PACLITAXEL AND CISPLATIN COMPARED WITH PACLITAXEL AND CISPLATIN AS FIRST-LINE TREATMENT IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED, UNRESECTABLE RECURRENT, OR METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA |
Prof. MA Brigette Buig Yue 馬碧如 教授 |
| 2019.342 | Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination with Pembrolizumab in Advanced Cancer |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2020.168 | A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma |
Prof. MA Brigette Buig Yue 馬碧如 |
| 2019.684 | An open-label, multi-center rollover protocol for continued characterization of safety and tolerability for subjects who have participated in a Novartis-sponsored spartalizumab study as single agent or in combination with other study treatments |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2020.591 | AN OPEN-LABEL, PHASE III STUDY OF PLATINUM-GEMCITABINE WITH OR WITHOUT NIVOLUMAB IN THE FIRST-LINE TREATMENT OF RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA |
Prof. MA Brigette Buig Yue 馬碧如 |
| 2020.367 | A FIRST IN-HUMAN, PHASE 1/2 STUDY OF CFI-402411, HEMATOPOIETIC PROGENITOR KINASE-1 (HPK1) INHIBITOR, AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH ADVANCED SOLID MALIGNANCIES |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2019.002 | A phase I/Ib, open-label, multi-center, study of DKY709 as a single agent and in combination with PDR001 in patients with advanced solid tumors |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2019.327 | A Phase Ib, open-label, multi-center study to characterize the safety, tolerability, and preliminary efficacy of TNO155 in combination with spartalizumab or ribociclib in selected malignancies |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2023.373 | A Phase I/II, Open-Label, Multi-Center Study of ALE.C04 (anti-Claudin-1 Antibody) as a Single Agent and in Combination with Pembrolizumab (anti-PD-1 antibody) in Adult Patients with Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma | Prof. MA Brigette Buig Yue |
| 2022.413 | A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer |
Prof. MA Brigette Buig Yue 馬碧如 |
| 2024.063 | NRG-HN011: A RANDOMIZED PHASE II STUDY OF NIVOLUMAB VERSUS NIVOLUMAB AND BMS-986016 (RELATLIMAB) AS MAINTENANCE TREATMENT AFTER FIRST-LINE TREATMENT WITH PLATINUM-GEMCITABINE-NIVOLUMAB FOR PATIENTS WITH EPSTEIN-BARR VIRUS-ASSOCIATED RECURRENT/METASTATIC NASOPHARYNGEAL CARCINOMA (REMAIN) | Prof. MA Brigette Buig Yue |
| 2024.095 | A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of ADG126 in Combination with Pembrolizumab (Anti-PD-1 Antibody) in Patients with Advanced/Metastatic Solid Tumors | Prof. MA Brigette Buig Yue |
| 2023.455 | Multi-modal Deep Learning of Multiomics Profiles, Radiology and Histopathology Images to Advance Colorectal Cancer Classification for Precision Oncology |
Prof. MA Brigette Buig Yue 馬碧如 |
| 2022.408 | Clinical application of circulating tumour DNA (ctDNA) assay for monitoring treatment response in advanced gastrointestinal cancers (‘PROCURE-liquid’ program) | Prof. MA Brigette Buig Yue |
| 2021.556 | A phase 2 trial of TAS 102 in recurrent/metastatic nasopharyngeal carcinoma |
Prof. MA Brigette Buig Yue 馬碧如 |
| 2021.630 | An Open-Label, Multicenter Phase 1b/2 Study of Nanatinostat and Valganciclovir in Patients with Advanced Epstein-Barr Virus- Positive (EBV+) Solid Tumors and in Combination with Pembrolizumab in Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma | Prof. MA Brigette Buig Yue |
| 2015.455 | A phase II, open-label, randomized controlled study of PDR001 in patients with moderately differentiated/undifferentiated locally advanced recurrent or metastatic nasopharyngeal carcinoma who progressed on standard treatment |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2017.357 | A Phase Ib/II, open label, multicenter study of MCS110 in combination with PDR001 in patients with advanced malignancies |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2014.662 | A phase Ib dose-finding study of BYL719 plus everolimus and BYL719 plus everolimus plus exemestane in patients with advanced solid tumors, with dose-expansion cohorts in renal cell cancer (RCC), pancreatic neuroendocrine tumors (pNETs), and advanced breast cancer (BC) patients. | Prof. MA Brigette Buig Yue |
| 2016.385 | A phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2014.357 | A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) ADMINISTERED WITH ERLOTINIB OR ALECTINIB IN PATIENTS WITH ADVANCED NON−SMALL CELL LUNG CANCER | Prof. MA Brigette Buig Yue |
| 2017.247 | Phase Ib study of PDR001 in combination with regorafenib in adult patients with previously treated metastatic microsatellite stable (MSS) colorectal cancer |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2017.404 | ElevatION: CRC-101: A Phase Ib study of PDR001 in combination with bevacizumab and mFOLFOX6 as first line therapy in patients with metastatic MSS colorectal cancer |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2016.443 | A PHASE III, OPEN LABEL, MULTICENTER, THREE-ARM, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZOLIZUMAB AND ATEZOLIZUMAB MONOTHERAPY VS. REGORAFENIB IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC COLORECTAL ADENOCARCINOMA |
Prof. MA Brigette Buig Yue 馬碧如 |
| 2015.442 | A Phase I/II, open label, multicenter study of the safety and efficacy of LAG525 single agent and in combination with PDR001 administered to patients with advanced malignancies |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2025.202 | A PHASE I DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY CLINICAL ACTIVITY OF RO7673396 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN PATIENTS WITH ADVANCED SOLID TUMORS HARBORING RAS MUTATION(S) | Prof. MA Brigette Buig Yue |
| 2024.483 | A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy | Prof. MA Brigette Buig Yue |
| 2024.659 | A Phase 2 Nonrandomized, Open-label, Multisite Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan in Participants With Gastrointestinal Cancers |
Prof. MA Brigette Buig Yue 馬碧如 |
| 2024.647 | A Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0022 Monotherapy and in Combination with Anti-cancer Agents in Participants with Tumours Harbouring a KRASG12D Mutation (ALAFOSS-01) | Prof. MA Brigette Buig Yue |
Page 164 of 262.